OT mobile menu

Search form


Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

Patients whose metastatic melanoma responded to pembrolizumab (Keytruda) immunotherapy had higher baseline frequencies of circulating immune T cells positive for CD8, programmed cell death protein 1 (PD-1), and Bim.

A new nationwide clinical trial comparing two groups of drugs for treating melanoma is marking a new era in the treatment of melanoma and how best to use the latest molecular tools.

In the real-world setting, about one-third of melanoma patients treated with ipilimumab had grade 3 or worse immune-related adverse events.

The US Food and Drug Administration (FDA) have granted a priority review for Merck’s anti-PD-1 agent pembrolizumab (Keytruda) as a first-line treatment of advanced melanoma, the company announced.

Interleukin (IL)-2 combined with imiquimod and topical retinoid therapy may help improve outcomes in melanoma patients with cutaneous metastases, according to a study published online August 11, 2015 in the Journal of the American Academy of Dermatology.

A major step is now occurring in the advancement of precision medicine in the treatment of cancer. A record number of cancer patients are now being enrolled in a trial that is like none other before and marks a new era in treating cancer.

Results of a study suggest that durable survival is possible in melanoma patients treated with MAPK inhibitors, and is perhaps similar to the survival observed with ipilimumab.


Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.